BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 11140086)

  • 1. [Cost effectiveness analysis of isoniazid preventive therapy to the contacts of tuberculosis patients under Japanese settings].
    Yoshiyama T
    Kekkaku; 2000 Nov; 75(11):629-41. PubMed ID: 11140086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of isoniazid chemoprevention in close contacts.
    Diel R; Nienhaus A; Schaberg T
    Eur Respir J; 2005 Sep; 26(3):465-73. PubMed ID: 16135730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberculosis vaccination versus isoniazid preventive therapy: a decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world.
    Sterling TR; Brehm WT; Moore RD; Chaisson RE
    Int J Tuberc Lung Dis; 1999 Mar; 3(3):248-54. PubMed ID: 10094327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis.
    Gourevitch MN; Alcabes P; Wasserman WC; Arno PS
    Int J Tuberc Lung Dis; 1998 Jul; 2(7):531-40. PubMed ID: 9661818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost of intensified case finding and isoniazid preventive therapy for HIV-infected patients in Battambang, Cambodia.
    Sutton BS; Arias MS; Chheng P; Eang MT; Kimerling ME
    Int J Tuberc Lung Dis; 2009 Jun; 13(6):713-8. PubMed ID: 19460246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latent tuberculosis infection in children: a call for revised treatment guidelines.
    Finnell SM; Christenson JC; Downs SM
    Pediatrics; 2009 Mar; 123(3):816-22. PubMed ID: 19255008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of preventing tuberculosis in physicians using tuberculin skin testing or a hypothetical vaccine.
    Nettleman MD; Geerdes H; Roy MC
    Arch Intern Med; 1997 May; 157(10):1121-7. PubMed ID: 9164378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of including tuberculin skin testing in an IPT program for HIV-infected persons in Uganda.
    Shrestha RK; Mugisha B; Bunnell R; Mermin J; Hitimana-Lukanika C; Odeke R; Madra P; Adatu F; Blandford JM
    Int J Tuberc Lung Dis; 2006 Jun; 10(6):656-62. PubMed ID: 16776453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of effectiveness of BCG vaccination and preventive therapy in Japanese settings, with special emphasis on the sensitivity and specificity of tuberculin testing].
    Yoshiyama T
    Kekkaku; 2002 Jan; 77(1):11-22. PubMed ID: 11855074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
    Jasmer RM; Snyder DC; Saukkonen JJ; Hopewell PC; Bernardo J; King MD; Kawamura LM; Daley CL;
    Clin Infect Dis; 2004 Feb; 38(3):363-9. PubMed ID: 14727206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting.
    Mandalakas AM; Hesseling AC; Gie RP; Schaaf HS; Marais BJ; Sinanovic E
    Thorax; 2013 Mar; 68(3):247-55. PubMed ID: 22717944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberculosis preventive therapy in HIV-infected persons: feasibility issues in developing countries.
    Hawken MP; Muhindi DW
    Int J Tuberc Lung Dis; 1999 Aug; 3(8):646-50. PubMed ID: 10460096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis.
    Salpeter SR; Sanders GD; Salpeter EE; Owens DK
    Ann Intern Med; 1997 Dec; 127(12):1051-61. PubMed ID: 9412307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The evaluation of close contact case of pulmonary tuberculosis patients enrolled to Eskisehir Deliklitas Tuberculosis Control Dispensary].
    Kolsuz M; Ersoy M; Küçükkebapçi C; Metintaş M; Uçgun I; Erginel S
    Tuberk Toraks; 2003; 51(3):282-8. PubMed ID: 15143407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
    Johnson KT; Churchyard GJ; Sohn H; Dowdy DW
    Clin Infect Dis; 2018 Sep; 67(7):1072-1078. PubMed ID: 29617965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reform of Japan's NTP and its technical perspectives].
    Mori T
    Kekkaku; 2004 Oct; 79(10):587-604. PubMed ID: 15631111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study.
    Shayo GA; Chitama D; Moshiro C; Aboud S; Bakari M; Mugusi F
    BMC Public Health; 2017 Jul; 18(1):35. PubMed ID: 28724374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preventive measures against tuberculosis in working facilities and companies].
    Suzuki K; Satou K
    Kekkaku; 2007 Mar; 82(3):201-16. PubMed ID: 17444125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia.
    Foster S; Godfrey-Faussett P; Porter J
    AIDS; 1997 Jun; 11(7):919-25. PubMed ID: 9189218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study.
    Azadi M; Bishai DM; Dowdy DW; Moulton LH; Cavalcante S; Saraceni V; Pacheco AG; Cohn S; Chaisson RE; Durovni B; Golub JE
    Int J Tuberc Lung Dis; 2014 Dec; 18(12):1443-8. PubMed ID: 25517809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.